<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Frequently encountered opioids</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Frequently encountered opioids</h1>
<div class="graphic"><div class="figure"><div class="ttl">Frequently encountered opioids</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="15%"></colgroup><colgroup width="55%"></colgroup> <tbody> <tr> <td class="subtitle1">Source</td> <td class="subtitle1">Serum half-life (hours)*</td> <td class="subtitle1">Approximate equivalence to 10 mg morphine injection (mg)</td> <td class="subtitle1">Important clinical features</td> </tr> <tr> <td class="subtitle2_left" colspan="4">IMPORTANT: The doses included here are NOT recommended for the initiation of therapy; they provide equivalents for the purpose of comparing different opioids.</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Natural</td> </tr> <tr> <td class="indent1">Morphine</td> <td>1.9 +/– 0.5</td> <td> <p>10 SC/IM/IV</p> 30 PO</td> <td> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Codeine</td> <td>2.9 +/– 0.7</td> <td> <p>75 SC/IM/IV</p> 130 to 200 PO</td> <td>Metabolized by CYP2D6 to active drug (morphine). Metabolism and effects are subject to pronounced individual variability. Single oral doses over 65 mg tend to produce disproportionately greater adverse effects than analgesia.</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Semi-synthetic</td> </tr> <tr> <td class="indent1">Hydromorphone</td> <td>2.4 +/– 0.6</td> <td> <p>1.5 SC/IM/IV</p> 7.5 PO</td> <td>Hepatically metabolized to metabolites that can accumulate in organ failure and prolong effects. Some metabolites have been linked to neurotoxicity.</td> </tr> <tr> <td class="indent1">Oxycodone</td> <td>2.6 (2.1-3.1)</td> <td>20 to 30 PO</td> <td>Metabolized by CYP3A4 and 2D6. Prolonged effects and elevated serum concentrations with renal or hepatic insufficiency. May cause QTc prolongation.</td> </tr> <tr> <td class="indent1">Hydrocodone</td> <td>4.24 +/– 0.99</td> <td>30 PO</td> <td> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Diacetylmorphine (diamorphine, heroin)</td> <td> </td> <td>5 SC</td> <td>Highly lipophilic causing more rapid CNS effects than morphine. Largely metabolized to morphine. Due to abuse potential is not available for clinical use in many countries.</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Synthetic</td> </tr> <tr> <td class="indent1">Meperidine</td> <td>3.2 +/– 0.8</td> <td> <p>75 to 100 SC/IM</p> 300 PO</td> <td>Excitatory neurotoxicity may occur when normeperidine, a renally-eliminated metabolite, accumulates.</td> </tr> <tr> <td class="indent1">Methadone</td> <td>27 +/– 12</td> <td>10 SC/IM/IV Highly variable. See clinical features.</td> <td>Used in opioid substitution therapy. Can cause QTc prolongation. May be far more potent than indicated in this table. Metabolized by CYP3A4. Due to its highly variable and prolonged half-life (up to 150 hours), methadone has the highest risk among opioids of accumulation and toxicity during initial titration and after changes in dose.</td> </tr> <tr> <td class="indent1">Tramadol</td> <td>5.5 (4.5-7.5)</td> <td>50 to 100 PO<sup>¶</sup></td> <td>Usual initial dose for mild analgesia shown; NOT equivalent to parenteral morphine 10 mg. Effects NOT completely reversed by naloxone. Noted to cause seizures. Metabolized by CYP2D6 and 3A4. Subject to interactions including serotonin excess.</td> </tr> <tr class="divider_bottom"> <td class="indent1">Fentanyl</td> <td>3.7 +/– 0.4</td> <td>0.05 to 0.1 SC/IM/IV</td> <td>Short acting when administered IV/IM as a single dose. Highly lipophilic. Parent drug accumulates with repeated or prolonged administration.</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Agonist/antagonist</td> </tr> <tr class="divider_bottom"> <td class="indent1">Pentazocine</td> <td>2 to 3</td> <td> <p>30 to 60 SC/IM</p> 75 to 150 PO</td> <td> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Partial agonist</td> </tr> <tr class="divider_bottom"> <td class="indent1">Buprenorphine</td> <td>2.33 +/– 0.24</td> <td> <p>0.3 to 0.4 IM/IV</p> 0.4 SL</td> <td>Used in opioid substitution therapy. Significantly longer duration of effect than 10 mg parenteral morphine. Metabolized by and subject to interactions involving CYP3A4.</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Gastrointestinally insoluble - not analgesic</td> </tr> <tr> <td class="indent1">Diphenoxylate</td> <td> </td> <td>2.5 to 5 PO (anti-diarrheal dose)<sup>¶</sup></td> <td>Poor solubility limits potential for parenteral injection and abuse. Usually formulated with atropine (United States trade name Lomotil, 0.025 mg atropine and 2.5 mg diphenoxylate) to further decrease abuse potential.</td> </tr> <tr> <td class="indent1">Loperamide</td> <td> </td> <td>2 to 4 PO (anti-diarrheal dose)<sup>¶</sup></td> <td>CNS depression and cardiac conduction disturbances are observed in large acute and chronic supratherapeutic ingestions.</td> </tr> </tbody></table></div><div class="graphic_footnotes">SC: subcutaneous; IM: intramuscular; IV: intravenous; PO: oral; SL: sublingual; CNS: central nervous system.<br/>* Half-life and equal analgesic dosing approximations apply only to immediate release or SQ/IM preparations, single dose, in opioid naive patients. The actual duration of effect may be longer or shorter than suggested by the serum half-life depending upon the dose, the patient's tolerance, the presence of active metabolites, organ function, and redistribution of the drug.<br/>¶ Not a dose equivalent. Usual initial dose shown.</div><div id="graphicVersion">Graphic 70480 Version 10.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
